Comprehensive historical analysis of global market for Erosive Esophagitis has thoroughly analyzed in this report. It offers data and insights from 2019-2022, and provides extensive market forecasts from 2023-2032 by region/country and subsectors. It covers the price, sales volume, revenue, historical growth, gross margin, and future outlooks for the Erosive Esophagitis market.

 The Global erosive esophagitis treatment market Size is expected to grow from USD 1.7 billion in 2025 to USD 3.19 billion by 2035, at a CAGR of 6.5% during the forecast period 2025-2035. 

The report includes growth prospects in the global Erosive Esophagitis market by type, application, sub segement and region and QMI has compiled a comprehensive detailed research report to offer insights. The report details consumption in the Healthcare and other sectors. Regional coverage spans North America, Europe, and rest of the world including Asia Pacific.

Leading players of Erosive Esophagitis including:

1. Phathom Pharmaceuticals, Inc.
2. Sun Pharmaceutical Industries Ltd.
3. Sebela Pharmaceuticals
4. Takeda Pharmaceutical Company Limited
5. Cinclus Pharma
6. AstraZeneca plc
7. Pfizer Inc.
8. GlaxoSmithKline plc
9. Johnson & Johnson
10. Merck & Co., Inc.

Request To Download Free Sample copy of the report @ https://www.sphericalinsights.com/request-sample/4656

Market split by Segement, can be divided into:

 By Drug Type

• Proton Pump Inhibitors (PPIs)
• H2 Receptor Antagonists (H2RAs)
• Antacids
• Cytoprotective Agents
• Prokinetic Agents
• Combination Therapies

 By Stage of Therapy

• First-Line Therapy
• Second-Line Therapy
• Rescue Therapy

Market segment by Region/Country including:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

Check discount for this report: https://www.sphericalinsights.com/request-discount/4656

In January 2026, Sebela Pharmaceuticals submitted an NDA for tegoprazan to the FDA for three indications: non-erosive reflux disease (NERD), erosive esophagitis (EE) healing, and EE maintenance. This represents a major pipeline event for EE treatment.

In April 2025, Sebela Pharmaceuticals reported positive topline results from its Phase III TRIUMpH program for tegoprazan, demonstrating faster and more effective healing of EE compared to PPIs.

In February 2025, CDSCO in India approved fexuprazan hydrochloride (40?mg) for EE treatment. Sun Pharma introduced Fexuprazan (FEXUCLUE) tablets in India as a new potassium?competitive acid blocker indicated for all grades of erosive esophagitis, reflecting regulatory progress in a key emerging market.

In July 2024, Phathom Pharmaceuticals received FDA approval for VOQUEZNA (vonoprazan) for EE. The FDA did approve VOQUEZNA® (vonoprazan) for the treatment of erosive GERD/erosive esophagitis (healing and maintenance, relief of heartburn), marking the first major innovation in acid?suppressing therapy in decades.

Access full Report with Table of Content @ https://www.decisionsadvisors.com/reports/erosive-esophagitis-treatment-market

Whats covered in the report?

• 1. Overview of the Erosive Esophagitis market.
• 2. The current and forecasted regional (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa) market size data for the Erosive Esophagitis market, based on segement.
• 3. Erosive Esophagitis Market trends.
• 4. Erosive Esophagitis Market drivers.
• 5. Analysis of major company profiles.

Reasons to buy this Market Report:

1. Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Erosive Esophagitis market.

2. Use the SWOT analysis to determine the competitive intensity and therefore attractiveness of the emerging Erosive Esophagitis Industry.

3. Leading company profiles reveal details of key Erosive Esophagitis market players emerging five operations and financial performance.

4. Add weight to presentations and pitches by understanding the future growth prospects of the emerging Erosive Esophagitis market with five year historical forecasts.

5. Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region.

6. Extensive information on factors that will amplify the growth of the Erosive Esophagitis market over the upcoming seven years

7. Accurate estimation of the global Erosive Esophagitis market size

8. Exact estimations of the upcoming trends and changes observed in the consumer behavior

9. Growth of the global Erosive Esophagitis market across the North & South America, EMEA, Asia Pacific, and Latin America

10. Information about Erosive Esophagitis market growth potential

11. In-depth analysis of the industry’s competitive landscape and detailed information vis-a-vis on various vendors

12. Furnishing of detailed information on the factors that will restrain the growth of the Erosive Esophagitis market

About the Spherical Insights

Spherical Insights is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.

Contact Us:

Company Name: Spherical Insights

Email: [email protected]

Phone: +1 303 800 4326 (US)

Follow Us: LinkedIn | Facebook | Twitter